Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previous participation in qualifying PsA study involving tofacitinib~Exclusion Criteria:~* Time from End of Study visit of qualifying study is \>3 months.~* Pregnant female, breastfeeding female or female of childbearing potential unwilling or unable to use highly effective birth control for duration of study and one ovulatory cycle thereafter.~Sub-study Inclusion Criteria:~* Subjects who have completed at least 24 months of treatment with tofacitinib in the extension study~* Subjects on a stable oral dose of methotrexate (maximum dose 20 mg per week)~Sub-study Exclusion Criteria:~-Subjects who are receiving methotrexate by a route other than oral

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).